Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.
Scroll Up
Scroll Down

Unified Laboratory Intelligence for Impurity Resolution Management
Bookmark and Share

ACD Labs

Maximizing the effective patent life of a marketed drug is one of the main priorities for researchers. According to a March 2010 article in Nature, the estimated average cost for pharmaceutical companies to bring a new chemical entity (NCE) to market is approximately 1.8 billion and requires 13.5 years on average. Identifying and characterizing an impurity in a couple of days less time can literally equate to a gain of a million dollars in net present value. Being able to do this repeatedly as impurities are encountered through the drug development and acceptance of a drug substance can shave weeks, or even months, off the time to market, increasing returns by millions of dollars.

Unified Laboratory Intelligence (ULI) is a category of R&D informatics that combines software, algorithmic tools, and databases to form a scalable platform for the collection and unification of chemical, structural, and analytical data. ULI accumulates information and knowledge from successive projects across different chemistry disciplines to create a one-to-many chemical intelligence-from-information ‘live’ cycle. With ULI, scientists can easily search and quickly retrieve ‘live’ data to gain and apply intelligence and insight that improves decision-making. 

Further Information


Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos